Regeneron Says Drug Approval Irrelevant In Antitrust Case
Regeneron told a Delaware federal court the recent regulatory approval of a new cholesterol drug is irrelevant to its case accusing Amgen of bundling Repatha with other medications, as the court...To view the full article, register now.
Already a subscriber? Click here to view full article